Abbott LaboratoriesvsBicara Therapeutics

ABT and BCAX stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$103.00

Value $179B

-0.84%
ABT's page

BCAX

Bicara Therapeutics Inc.

$8.44

Value $553M

-7.46%
BCAX's page

Abbott Laboratories (ABT) has a market value of $179B and Bicara Therapeutics (BCAX) $553M. Over the last year, with dividends, ABT moved -16.3% and BCAX -44.4%. Dividend yield: ABT 2.45%, BCAX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$179B

    BCAX$553M

    ABT is 324 times BCAX

  • Revenue, 12 months

    ABT$48.2B

    BCAX–

  • Net income, 12 months

    ABT$4.7B

    BCAX-$220M

  • Operating margin

    ABT13.8%

    BCAX–

  • ROIC

    ABT6.3%

    BCAX-30.6%

    36.9 points apart

  • P/E

    ABT38.1

    BCAX–

  • Dividend yield

    ABT2.5%

    BCAX0.0%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-16.3%

BCAX-44.4%

50100150DecFebAprJunAugOct
Returns by period
PeriodABTWith dividendsBCAXWith dividends
1 year since November 19, 2025-16.3%Price -18.4%-44.4%Price -44.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesBCAXBicara Therapeutics

Valuation

ABTBCAX
Valuation
Price$103.00$8.44
Market value$179B$553M
Enterprise value (EV)$206B$110M
P/E38.1–
P/E, 5-year median33.7–
P/B3.51.4
EV/EBIT31.0–
Free cash flow yield3.8%–

Results and growth

ABTBCAX
Results and growth
Revenue, 12 months$48.2B–
Net income, 12 months$4.7B-$220M
Free cash flow, 12 months$6.8B-$163M
Earnings per share, 12 months$2.69-$3.47
Revenue growth, year on year5.7%–
Revenue growth a year, past+5.1%over 5 years–
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTBCAX
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%–
Net margin9.8%–
ROIC6.3%-30.6%
ROE9.1%-50.1%

Balance sheet

ABTBCAX
Balance sheet
Cash$4.3B$442M
Total debt$31.2B$880.0K
Net debt / EBITDA3.3–
Interest cover6.7×–

Dividends and buybacks

ABTBCAX
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or BCAX

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Bicara Therapeutics?

By market value, Abbott Laboratories ($179B) is about 323.9 times Bicara Therapeutics ($553M), at today's prices.

How did ABT and BCAX stock do over the last 1 years?

Since November 19, 2025, ABT's price moved -18.4% and BCAX's -44.4%. With dividends: ABT -16.3% (-16.3% a year), BCAX -44.4% (-44.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or BCAX?

The dividend yield at today's price is 2.45% for Abbott Laboratories and none for Bicara Therapeutics. Over the last twelve months they paid $2.52 and – per share.

Which is the better investment, Abbott Laboratories or Bicara Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.